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Abstract
Background: Poor access to prompt and effective treatment for malaria contributes to high mortality and severe
morbidity. In Kenya, it is estimated that only 12% of children receive anti-malarials for their fever within 24 hours. The
first point of care for many fevers is a local medicine retailer, such as a pharmacy or chemist. The role of the medicine
retailer as an important distribution point for malaria medicines has been recognized and several different strategies
have been used to improve the services that these retailers provide. Despite these efforts, many mothers still
purchase ineffective drugs because they are less expensive than effective artemisinin combination therapy (ACT).
One strategy that is being piloted in several countries is an international subsidy targeted at anti-malarials supplied
through the retail sector. The goal of this strategy is to make ACT as affordable as ineffective alternatives. The
programme, called the Affordable Medicines Facility - malaria was rolled out in Kenya in August 2010.
Methods: In December 2010, the affordability and accessibility of malaria medicines in a rural district in Kenya
were evaluated using a complete census of all public and private facilities, chemists, pharmacists, and other malaria
medicine retailers within the Webuye Demographic Surveillance Area. Availability, types, and prices of anti-malarials
were assessed. There are 13 public or mission facilities and 97 medicine retailers (registered and unregistered).
Results: The average distance from a home to the nearest public health facility is 2 km, but the average distance to the
nearest medicine retailer is half that. Quinine is the most frequently stocked anti-malarial (61% of retailers). More
medicine retailers stocked sulphadoxine-pyramethamine (SP; 57%) than ACT (44%). Eleven percent of retailers stocked
AMFm subsidized artemether-lumefantrine (AL). No retailers had chloroquine in stock and only five were selling
artemisinin monotherapy. The mean price of any brand of AL, the recommended first-line drug in Kenya, was $2.7 USD.
Brands purchased under the AMFm programme cost 40% less than non-AMFm brands. Artemisinin monotherapies cost
on average more than twice as much as AMFm-brand AL. SP cost only $0.5, a fraction of the price of ACT.
Conclusions: AMFm-subsidized anti-malarials are considerably less expensive than unsubsidized AL, but the price
difference between effective and ineffective therapies is still large.
Background
Malaria is one of the most important of the parasitic dis-
eases of mankind, causing almost 5 billion clinical episodes
in endemic countries annually, with more than 90% of this
burden occurring in sub-Saharan Africa [1]. Malaria can
be successfully treated with an appropriate course of anti-
malarials. However, if treatment is delayed, malaria can
quickly become life-threatening, particularly for children.
Inappropriate treatment with ineffective drugs, especially
drugs to which a high degree of resistance exists, can also
lead to severe complications and death. For these reasons,
prompt and effective treatment is a cornerstone of malaria
control programmes.
In many countries, treatment for fever and malaria
through self-medication with anti-malarials bought over-
the-counter (OTC) from drug vendors is common [2-5].
This channel is increasingly being considered as a viable
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any medium, provided the original work is properly cited.option for improving drug availability to malaria infected
individuals, particularly those located further away from
public health facilities [6-10]. For example, in rural Tan-
z a n i aw h e r et h em a j o r i t yo fp e o p l es e e km a l a r i at r e a t -
ment from retail drug sellers, the government established
accredited drug dispensing outlet (ADDO) as a private
sector supplement for the distribution of subsidized ACT
in order to increase access to the first-line anti-malarial
in rural and underserved areas [8].
However, accessing effective anti-malarials through
these outlets remains problematic [2,6,11]. Several factors
contribute to poor access, chief among them being cost,
and distance to an outlet [12]. Chima et al [13] in analyz-
ing the cost of malaria treatment in Africa found it ranged
between US$0.41 and US$3.88 per person, which is
beyond a household with a modest income. In Burundi,
artemisinin combination therapies (ACT) in the private
retail sector cost the equivalent of 1.5 days wages [14].
The situation is not any different in rural Kenya where
malaria is endemic, and the cost of effective treatment
remains prohibitive to the most vulnerable [15].
Recently, a global subsidy has been launched that aims
to reduce the price of effective artemisinin combination
therapy (ACT) supplied through the retail sector and
make them more affordable than ineffective, older anti-
malarials. This approach not only addresses the underlying
economic considerations for the consumer, but also allows
control of the quality of anti-malarials purchased by this
programme. The subsidy, entitled Affordable Medicines
Facility-malaria (AMFm) is a recent initiative by the inter-
national community intended to address ACT pricing and
improve coverage. AMFm was launched in Kenya in
August 2010.
Five months after the roll-out of AMFm in Kenya, a sur-
vey was undertaken of all public health facilities and
malaria medicine retailers, including private clinics, che-
mists, pharmacies and other specialized drug stores, that
serve residents of the Webuye Health and Demographic
Surveillance Site (WHDSS) in western Kenya. The survey
was designed to measure three dimensions of access to
ACT; accessibility, availability, and affordability. The avail-
able anti-malarial drugs, reported stock-outs, types and
brand names, and prices of anti-malarials in the WHDSS
in western Kenya were measured following the roll-out of
the AMFm subsidy. The average distance from a house-
hold to the nearest public health facility and the distance
to the nearest medicine vendor were estimated to under-
stand the reasons for choosing treatment through malaria
medicine retailers.
Methods
Study area
The study was carried out in the Webuye Health and
Demographic Surveillance Site (WHDSS). The WHDSS
is located in Bungoma East District in Western Province,
Kenya. The WHDSS provides longitudinal surveillance
through twice-annual household surveys to a population
of 70,000 people living in six administrative sublocations.
Malaria transmission is year round with seasonal peaks
following the rains in June. Transmission is moderate to
high. EIR is estimated to be 29 infectious bites per person
per year and parasite prevalence is 55% in asymptomatic
children during the rainy season [16]. Most families
engage in subsistence farming and animal husbandry.
There are large sugar cane plantations and processing
plants that employ seasonal labour from the community.
Census of facilities
All the major roads in the study area were mapped using
a Garmin E-trex handheld GPS unit. Major town centres
were marked. A team of 10 fieldworkers was trained to
use the GPS units and each was sent out on a motorbike
to cover a specific area. The field worker started in a
designated market centre and identified all potential
medicine retailers and private health facilities. They took
the name and GPS coordinates of each one. They then
asked the shop owner if there were any other places to
buy medicines. They visited the next medicine retailer
and continued inquiring about other medicine retailers
until no new retailers were identified. In order to identify
all retailers that might be accessed by those living within
the DSS, all medicine retailers and clinics within 5 km of
the border of the DSS were included, except on the
north-eastern border, where a river marks the boundary
of the DSS. A complete listing of public health facilities
was obtained from the District Health Management
Team. Each one was visited and the coordinates were
recorded.
Survey
Field workers were trained to administer the survey tool
and a pilot study was conducted outside of the study area.
Field workers visited each medicine retailer mapped dur-
ing the census. Shops that sold general goods including a
small selection of painkillers or other medicines were not
included. Chemists, pharmacists, medicine shops, private
clinics that sold medicines, and agrovets that also carried
human medicine were included. Public health facilities
were interviewed after obtaining permission from the Dis-
trict Medical Officer of Health for Bungoma East district.
The survey included elements from two questionnaires
used in previous studies of retail outlets: (1) the ACTwatch
Outlet Survey questionnaire [17] and (2) Provider Survey
for the evaluation of subsidized ACT in retail outlets in
Western Kenya [18].
All drug shops, pharmacists, chemists and private clinics
are referred to as ‘medicine retailers’. Those retailers that
included the term ‘clinic’ in their name were relatively few
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were no more likely to have diagnostics available or a
trained health worker on staff. They sell medicines to their
customers and are also a target for the AMFm subsidy so
it seemed appropriate to analyze them with other retailers
for the purpose of this study.
Data analysis
Paper questionnaires were double entered into a Microsoft
Access database and checked for consistency. Discrepan-
cies were resolved by referring to the hard copies. Access
tables were exported into Stata v10 for analysis. Maps
were produced using ArcGIS10 (ESRI). The price of anti-
malarials are reported in USD and KSh. The dollar value
was arrived at using a conversion of 80 Ksh per USD.
Ethical considerations
Prior to data collection, meetings were held with all the
chiefs, assistant chiefs, and village elders in the commu-
nities where the study was proposed. Approval was sought
from these community leaders and they disseminated
information about the study to their communities. At the
conclusion of the study, results were reported to the com-
munities during health outreach activities. The study was
reviewed and approved by Moi University Institutional
Research and Ethics Committee and Duke University
Institutional Review Board.
Results
Survey
117 medicine retailers were initially identified during the
mapping. Of those, nine did not sell malaria medicines, 13
were found to have closed between the mapping (August)
and the survey (November), and three were not found
open after three visits. At the time of the survey, 11 new
medicine retailers were identified that had been estab-
lished between the mapping and the survey. There were
14 eligible public or mission facilities and 13 were available
to be interviewed. In total, 130 staff members representing
97 shops and private clinics and 13 public/mission facil-
ities were included in the analysis.
Accessibility of facilities and medicine retailers
Two dimensions of accessibility of public facilities and
shops to the population they serve were measured - dis-
tance and operating hours. The Webuye DSS population
is served by 13 government-owned health facilities; nine
dispensaries, two health centres, one hospital and one sub-
district hospital. There is one mission-run hospital in the
northern part of the district. In addition to the public facil-
ities, 97 medicine retailers were surveyed, including drug
shops, pharmacies, chemists and private clinics (Figure 1).
Most medicine retailers were located along the roads and
near market centres. Based on the population estimates of
the six sub-locations in the DSS area, there is approxi-
mately one health facility per 6,000 people and one shop
per 800 people. Using the GPS coordinates of the facilities
and medicine retailers and the GPS coordinates of the
households in the WHDSS, the average distance from a
household to a public health facility was estimated to be
2 km. The average distance to a medicine retailer was
1k m .
Most medicine retailers had weekend hours. 85% are
open on Saturday and 42% are open on Sunday (includ-
ing 6 of 12 private clinics). 85% were open after 5 pm on
the weekdays and 8% were open after 7 pm on weekdays.
Government-owned and mission facilities had more lim-
ited operating hours. Only public hospitals and sub-dis-
trict hospitals were open on the weekend. Health centres
and dispensaries open on weekdays between 8 am to 4 or
5 pm. One health centre and one dispensary reported
having weekend hours.
Availability of anti-malarials
For each retailer or facility, the types of medicines in stock
on the day of the survey were recorded, stockouts of those
drugs in the last one month, and drugs normally stocked
but not available on the day of the survey (Table 1: shop
characteristics). “Clinics” and all other retailers are
described separately in the table to illustrate the similarity
between these categories. However, since there is no func-
tional difference between them as noted in the Methods
section, they are grouped together for all other analyses.
On average, a malaria medicine retailer stocked three
different types or brands of anti-malarials. SP was the
most often stocked drug in the retail sector (32% of all
malaria medicines available on the day of the survey), fol-
lowed by quinine (30%). Forty-four percent of medicine
retailers had artemether lumefantrine in stock that day,
57% had SP in stock, and 61% had quinine. 18 additional
medicine retailers reported stocking AL but were out of
stock on the day of the survey. Eleven retailers (11%)
stocked the brand name “Artefan “ which is the AMFm-
subsidized brand of AL. These retailers were distributed
throughout the study area (Figure 1). Other artemisinin
combination therapies that were in stock at the time of
the survey were dihydroartemisinin piperaquine (10 retai-
lers), artemisinin piperaquine (one retailer), and artesunate
- sulphamethoxypyrazine-pyrimethamine (one retailer).
Only five malaria medicine retailers had uncombined arte-
misinin (5%). 3% of all drugs were past their expiry date.
There were no medicine retailers with chloroquine.
Despite the fact that quinine was the second most fre-
quently recorded drug and found in more retailers than
other types of anti-malarials, only 12% of retailers reported
quinine as the most commonly sold drug. 39% of malaria
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medicine and an equal percent reported SP as the most
frequently sold anti-malarial.
Seven retailers (7%) normally stocked anti-malarials,
but were completely out of anti-malarials on the day of
the survey. Forty-four percent of malaria medicine
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Figure 1 Map of Webuye Health and Demographic Surveillance Site and surrounding district. Public health facilities, private clinics,
medicine retailers stocking AMFm AL, and all other medicine retailers are indicated.
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Page 4 of 8retailers reported being stocked-out of all anti-malarials
at some time, 14% reported this happening on a weekly
basis and 25% reported this as a monthly occurrence.
Five of 13 (38%) public health facilities reported being
out of stock of all anti-malarials at some time. They
reported this as either a weekly or monthly occurrence.
For both retailers and government facilities, AL was not
significantly more likely to have been out of stock in the
past month or on the day of the survey than SP, amo-
diaquine or quinine.
When asked how they decide which drugs to stock, the
overwhelming majority of respondents (65 of 97) reported
customer demand as the driving factor, 27 reported being
influenced by MOH guidelines or local health profes-
sionals, and eight reported wholesale price as being an
important consideration. No respondents reported adver-
tisement or incentives from pharmaceutical companies as
influencing their decisions. The respondants were also
asked how they decided which anti-malarial to dispense
when multiple anti-malarials were in stock. Customer
choice drove the decision about which anti-malarial to dis-
pense for about half of respondents while 22 (18%)
respondents reported weighing local health professional
advice and 17 (13%) decided which anti-malarial based on
the patient’ss y m p t o m s .
Affordability of anti-malarials
For each anti-malarial in stock, the price for a full treat-
ment course was recorded. The mean price for a course
of AL was 2.73 USD (SD = 1.95, Table 2). Prices for the
subsidized brand of AL, Artefan, ranged from 0.5 USD
to 2.5 USD (mean = 1.63 USD, SD = 1.3). For other
artemisinin combinations, the mean price was 4.23 USD
(SD = 0.84). The mean price for uncombined artemisi-
nin was 5.40 USD (SD = 3.81). SP was the least expen-
sive anti-malarial. The mean price for a dose of SP was
0.65 USD (SD = 0.33). Amodiaquine and quinine were
slightly more expensive than SP, but still considerably
less than AL (Table 2). Prices varied widely between
shops for the same brandname and dosage form of a
drug. A single brandname of quinine was found at 0.31
USD at one retailer and 5.63 USD in another. Similarly,
a single brand of SP was between 1.13 USD to 3.75
USD and Coartem
®, a brandname of AL, ranged
between 0.63 USD to 7.5 USD.
If a client didn’t have enough money for the medicine,
63% of retailers said they would give on credit and 18% of
shop workers said they would offer a cheaper alternative
or sell them only the number of tabs they could afford.
2 8 %s a i dt h e yh a v es o l das m a l l e rd o s ew h e nac u s t o m e r
demanded it and 57% said they have separated tabs from
packaging to sell to customers. Only 13% of respondents
said they would refuse to sell at all if the customer could
not afford the medicine. 61% of respondents said they
would refer a customer to another shop or a health facility
if they were out of stock of all anti-malarial medicines.
Discussion
This study explored three dimensions of access to anti-
malarials through the retail sector in a rural district in
Kenya following the implementation of a nation-wide anti-
malarial subsidy programme. Accessibility, availability and
affordability anti-malarials in the retail sector was com-
pared to the public sector facilities in the same district.
In this study, ‘accessibility’ is defined as physical access
to an outlet where anti-malarials may be obtained. Alba et
al reported that physical access was the most important
factor in determining whether a patient got an effective
anti-malarial. Patients living in a village with a shop or
health facility were four times more likely to get an ACT
within 48 hours of onset of fever [19]. Based on the results
Table 1 Shop and facility characteristics
Shops Private
clinics
a
Public
facilities
Total 85 12 13
Open on Saturday 41 9 5
Open on Sunday 18 6 4
Open after 7 pm weekdays 4 0 0
Mean number of staff 1.4 2.2 3.2
Mean No. of anti-malarials in stock 2.8 2.4 2.8
Mean No. of anti-malarials out of stock 2.3 1.6
AL in stock 37 6 13
SP in stock 48 7 7
b
Artemisinin monotherapy in stock 4 1 0
Experience regular stockouts of all anti-
malarials
40 3 5
Out of stock of all anti-malarials on day of
survey
70 0
Mean price of AL 210
Ksh
175
Ksh
-
c
a. Private clinic is defined as a retailer with the word ‘clinic’ in the name
b. SP is used for IPTp in public facilities
c. AL is free in public health facilities
Table 2 Prices of anti-malarials
Mean price for
treatment in USD (KSh)
Range USD
(min, max)
AL 2.73 (218) (0.38, 7.50)
AMFm AL
a 1.63 (130) (0.50, 3.75)
Other 2.86 (229) (0.38, 7.50)
ACT (non-AL) 4.23 (338) (3.13, 5.63)
Artemisinin
Monotherapy
5.40 (432) (1.50, 10.5)
SP 0.65 (52) (0.19, 1.50)
Quinine 1.21 (97) (0.25, 5.63)
Amodiaquine 0.80 (64) (0.38, 1.13)
aArtefan, AMFm subsidized brand
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through the retail sector when considering the abundance
of malaria medicine retailers, their proximity to house-
holds, and longer opening hours than public facilities. On
average, households travel twice the distance to attend a
public health facility than to reach a malaria medicine
retailer. Most public health facilities do not offer weekend
opening hours. Hospitals and health centres do open on
Saturdays and Sundays (hospitals only), but these facilities
are few and located near the peri-urban centre, away from
the rural communities. In contrast, 85% of the malaria
medicine retailers offer Saturday opening hours and nearly
half open on Sunday, a factor shown to contribute to
treatment seeking in the retail sector in other studies [2].
AL has been the recommended first line treatment for
uncomplicated malaria in Kenya since 2006. SP is still
widely available and used, but resistance is common; more
than 80% of infections are resistant [20] resulting in 22-
40% treatment failure [21,22]. Forty-four percent of
malaria medicine retailers had AL in stock on the day of
the survey, and an additional 20% reported stocking it but
were out of stock that day. Thirty-nine percent of malaria
medicine retailers reported that AL was the most com-
monly sold drug. In contrast, a study in a neighboring dis-
trict showed almost no retail sales of AL in 2008, only two
years before our study [18].
Only seven malaria medicine retailers were completely
stocked out of anti-malarials on the day of the survey,
although a quarter reported stockouts as a regular occur-
rence. SP and quinine were the most frequently stocked
drug, together making up over 60% of all the drugs
observed. On a positive note, very few malaria medicine
retailers sold uncombined artemisinin and none reported
carrying chloroquine.
In public facilities, AL, SP, and quinine injections were
available. SP is provided to facilities for Intermittent Pre-
ventive Treatment in pregnancy (IPT-p) although it can-
n o tb er u l e do u tt h a tS Pi sb e i n gg i v e nf o rf e b r i l e
episodes. Although only five out of 13 public facilities
reported regular stockouts of anti-malarials, anti-malarial
shortages are a frequent problem in rural facilities in
Kenya [23].
Prices of anti-malarials varied widely between types and
between retailers. The same brandname sometimes varied
by an order of magnitude between retailers. It is possible
that medicine retailers procured the same brandname
from different wholesalers or other outlets leading to price
variability. It is likely that prices in the retail sector are not
‘fixed’ at the level of the consumer, particularly in the less
formal retail shops, but rather the price may be adjusted
based on the client’s ability to pay. Other studies have
shown that the decision about which drug to sell is often
dictated by what the patient can afford. In our study, med-
icine retailers reported separating blister packs of pills and
selling only the number of tablets that a client can afford.
Overall, less effective anti-malarials like SP and amodia-
quine were significantly less expensive than artemisinin
combination therapies. Non-AL ACT was more expensive
and less common. Uncombined artemisinin was more
expensive than AL or other types of ACT. In contrast to
our results, a study in Burundi found ACT in private retail
shops to be less expensive than quinine and amodiaquine
even without subsidies [14]. In Kenya, the minimum wage
is 2.5 USD per day. Although the average price of AL is
roughly equivalent to one-day’s wages, a criteria for afford-
ability proposed by the World Health Organization, unem-
ployment in Kenya is estimated to be 40% and most casual
workers found in our study area do not work every day of
the month. In the WHDSS area, the high price of ACT is
undoubtedly still an obstacle to accessing effective
treatment.
Pharmacies in Kenya are required to be registered and
only registered pharmacies are permitted to sell prescrip-
tion medicines. Even registered pharmacies in Kenya are
not legally permitted to sell ACT over-the-counter with-
out a prescription and unregistered medicine retailers are
not permitted to sell ACT at all, although both practices
are common. Under the current policy, the AMFm sub-
sidy would only benefit patients who have a prescription
either from a private facility or from a public facility where
AL was unavailable. There is some misalignment between
current policy in Kenya and the intention of the AMFm
subsidy. Tanzania has designated a special cadre of accre-
dited shops that are permitted to sell ACT over the coun-
ter. Establishment of Accredited Drug Dispensing Outlets
(ADDOs) and provision of subsidized ACT through this
channel has greatly improved and expanded access to
ACT [8,19]. However, the strategy hasn’t significantly
reduced the percent of older children and adults who pur-
chase SP for their fever [19] and only 30% of drug shops
carried AL [24]. The survey used for this report did not
specifically identify registered pharmacies, but according
to the Kenya Pharmacy and Poisons Board there are only
six pharmacies registered in the area, indicating that
the large majority of medicine shops in our study were
probably unregistered. Formalizing the sale of ACT over-
the-counter in Kenya through specialized or trained drug
vendors may increase the accessibility and availability of
subsidized AL.
Providing subsidized ACT through the retail sector is
intended to reduce the cost of effective drugs to below
that of ineffective therapies and increase the number of
fevers treated with an appropriate anti-malarial. A rando-
mized controlled trial in Kenya demonstrated a dramatic
improvement in the percent of children under-5 who
received AL for their fever after deployment of subsidized
AL in the retail sector [18]. A pilot evaluation of subsi-
dized ACT provided to wholesalers in three districts in
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number of patients who purchased ACT [25].
This is the first report of the effect of the international
subsidy of ACT through the retail sector. Country-wide
retail sector subsidies for AL through the AMFm pro-
gramme began in Kenya in August 2010, five months
before our survey. Between August and November 2010,
1.2 million treatment courses of subsidized AL (a single
brandname - Artefan) were procured and delivered to
Kenya. National media campaigns were used to raise
public awareness about the subsidy and the correct pri-
cing. The price of a treatment course of AL under the
subsidy is intended to be 0.5 USD (40 Ksh). In this study,
subsidized AL was significantly less expensive than other
brands, but still almost three times as expensive as SP.
However, the subsidy is applied at the level of the whole-
saler, and retailers set their own prices. In our survey,
only one shop was selling subsidized AL at the recom-
mended price.
Eleven percent of malaria medicine retailers in the
s t u d ya r e as t o c k e ds u b s i d i z ed AL. Nearly all retailers
with subsidized AL did not carry non-subsidized brands
(either in-stock or reported out-of-stock) which suggests
that these retailers may not have been selling AL prior to
the subsidy and the subsidy may have expanded the avail-
ability of AL. In addition, retailers with subsidized AL
were distributed throughout the study area (Figure 1)
and were not concentrated in the town centre.
It is interesting to speculate about how accessibility,
availability, and affordability impact treatment-seeking
decisions for febrile illnesses. Clearly, accessing anti-
malarials through medicine retailers is more convenient
than attending a public health facility for most families.
On the other hand, treatment is free in public facilities,
although families must also weigh transportation costs
and time investment to attend the public facility [2]. It is
also possible that patients perceive ‘free drugs’ as less
desirable or ineffective [26,27]. During frequent drug
shortages in public facilities, patients receive a prescrip-
tion and must buy the drug from a retailer. When drugs
are not available in facilities, many patients probably
bypass the facility and go directly to the retailer.
Our results also demonstrate an impact in the reverse
direction - customer demand, preference, and resources
influence which drugs are stocked in retail shops and
which drug a customer purchases. This is in agreement
with an exit survey of shop customers, which showed
that the majority of patients who visited a shop specifi-
cally asked for an anti-malarial, but only 16% asked for
an ACT. Asking for an ACT significantly increased the
likelihood of receiving one [14]. Shops are responsive to
customer demands and preferences which suggests that
leveraging customer awareness and demand could have a
significant positive impact on the effectiveness of the
AMFm subsidy. This also underscores the importance of
continuing public awareness campaigns and health edu-
cation messages in the implementation of AMFm.
Conclusions
In Kenya, only 12 percent of children receive an appropri-
ate anti-malarial for their fever within 48 hours of onset
[28]. The retail sector is an important source of anti-
malarials for fevers. Treatment was sought from a local
medicine retailer for 45% of children with fever in a nearby
rural district in Kenya [5]. A review of treatment-seeking
behaviour for fevers in Kenya reported that between 17
and 83% of fevers are treated with medicines purchased
from shops [3], including anti-malarials. Improving access
to effective anti-malarials through the retail sector could
be an efficient way to increase the percent of fevers that
are treated promptly and effectively.
The results reported here describing access to anti-
malarials in the retail sector generally agrees with previous
work. Anti-malarials in the retail sector are more accessi-
ble but less affordable than the public health sector. First-
line therapy for uncomplicated malaria, AL, is available in
nearly half of malaria medicine retailers, but is still more
expensive than ineffective drugs. Encouragingly, subsidized
drugs had already penetrated the market even in this rural
community only five months after the launch of the sub-
sidy. There is an opportunity to improve the impact of the
subsidy by leveraging customer demand to increase the
number of retailers stocking AL.
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